Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX.
Venhoff
Nils
N
Venhoff
Ana C
AC
Jayewardene
Anura L
AL
Aweeka
Fran
F
Lebrecht
Dirk
D
Walker
Ulrich A
UA
D000284:Administration, Oral; D019540:Area Under Curve; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D010919:Placebos; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014529:Uridine / Q000008:administration & dosage*; D015215:Zidovudine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
D010919:Placebos; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D014529:Uridine